 |
|
New Class of Anti-HIV Drugs
Joan Stephenson, PhD
JAMA. 1999;282:1994.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
San Francisco—While state-of-the-art combination antiretroviral therapy has had an enormous impact in extending and improving the lives of patients with HIV infection, clinicians are increasingly faced with the question of how to help patients who fail to respond to standard anti-HIV drugs because of emerging resistance or other factors. One strategy being pursued by researchers, with the hope of buying time for such patients, is the development of a class of drugs called fusion inhibitors.
HIV-1 fusion inhibitors are designed to block infection by preventing HIV from fusing with and inserting its genetic material into host cells. In contrast, other antiretroviral drugs work by interfering with HIV's ability to integrate its genetic material into the human genome or by blocking viral replication. Because such drugs work by a different mechanism than currently approved antiretroviral drugs, researchers hope this therapeutic strategy will help patients infected with HIV . . . [Full Text of this Article]
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Mode of Action of an Antiviral Peptide from HIV-1. INHIBITION AT A POST-LIPID MIXING STAGE
Kliger et al.
J. Biol. Chem. 2001;276:1391-1397.
ABSTRACT
| FULL TEXT
|
